Apellis: A Tactical Mispricing Ahead of the February 24 Earnings Call

The immediate event is clear. Apellis Pharmaceuticals' stock tumbled by about 14% after the company reported preliminary 2025 sales for its geographic atrophy drug, Syfovre, came in at $587 million, a 4% year-over-year decline. The drop was triggered by analyst commentary pointing to persistent copay assistance headwinds that have hit patient starts all year. This is the bear case: a blockbuster drug losing ground.

Yet this creates the core investment question: is the market overreacting to a temporary setback, pricing in a permanent decline? The counter-narrative is already emerging. The company's other key asset, the kidney disease drug Empaveli, is launching strongly. Apellis reported 267 patient starts in 2025, exceeding projections, and the drug pulled in $102 million in sales for the year. This isn't just a pipeline hope; it's a new revenue stream gaining traction.

The setup is now tactical. The stock trades at $22.58, a level that is 35% below its 52-week high. That gap from its recent peak, combined with the strong new launch, frames a potential mispricing. The February 24 earnings call will be the catalyst to test this thesis, offering a chance to see if the market's initial panic has created an entry point for a turnaround story.

Financial Mechanics: Cash Runway vs. Revenue Quality

The tactical setup hinges on two financial realities. First, the company has a robust cash position that provides ample time. Apellis ended 2025 with approximately $466 million in cash and cash equivalents, and management projects this, combined with expected product revenues, will be sufficient to fund operations to profitability. This is a critical buffer. It means the market's 14% panic over GA sales headwinds doesn't immediately threaten the company's ability to execute its strategy. The focus can shift from survival to the timing of a recovery.

Second, the quality of the new revenue stream is strong. The launch of the kidney drug Empaveli is showing high early adoption. The company reported 267 cumulative patient start forms in 2025, achieving more than 5% market penetration in its initial indications within just five months. This isn't a slow ramp; it's a rapid uptake that signals robust underlying demand and effective commercial execution. It's a new, growing cash flow engine that wasn't present a year ago.

This creates a clear risk/reward dynamic. The cash runway allows the GA story to play out without immediate pressure. Meanwhile, the strong launch of Empaveli provides a tangible floor for revenue and a path to profitability. The February 24 earnings call will be the first chance to see if management can articulate a credible plan to address the GA headwinds while accelerating the Empaveli momentum. For now, the financial mechanics support a patient, tactical approach.

Catalysts and Risks: The February 24 Setup

The immediate forward-looking event is the February 24 earnings call. This is the catalyst that will determine if the current mispricing holds or corrects. The call will provide final 2025 numbers and, more importantly, 2026 guidance. Investors will scrutinize management's plan to address the persistent headwinds and accelerate the Empaveli launch. Any shift in tone or detail on the GA recovery path will move the stock.

A potential near-term growth driver is the regulatory submission for a new Syfovre prefilled syringe planned in H1 2026. This could be a key lever for patient adoption, but analysts note it's not a near-term sales boost. The focus remains on resolving the copay assistance issues that have hit patient starts.

The primary risk is that the GA copay assistance headwinds persist, potentially delaying a sales recovery. While total injection demand grew 17% year-over-year, sales declined 4% to $587 million. This disconnect is the core problem. If management cannot articulate a clear path to resolving this, the stock's rally from the 14% drop could falter.

Analyst sentiment is skewed positive, providing a floor. Bank of America recently upgraded the stock to Buy, and the average price target sits at $33.53. This suggests many see the strong Empaveli launch as a sufficient offset to GA's troubles. Yet insider selling in January adds a note of caution.

The setup is clear. The February 24 call is the event that will test whether the market's initial panic over GA sales was a tactical mispricing or a signal of deeper trouble. The outcome will hinge on guidance for 2026 and a credible plan to tackle the headwinds.